Breast Cancer in Canadian Women

被引:1
|
作者
Heather Bryant
机构
[1] Division of Population Health and Information, Alberta Cancer Board, Calgary
基金
英国医学研究理事会;
关键词
Breast Cancer; Breast Cancer Risk; Mammographic Screening; Raloxifene; Tamoxifen;
D O I
10.1186/1472-6874-4-S1-S12
中图分类号
学科分类号
摘要
Health issue: Although lung cancer is the leading cause of cancer deaths for Canadian women, breast cancer is the most frequently diagnosed. About 5400 women are expected to die from this disease in 2003. In 1998, a woman's lifetime risk of breast cancer was about one in nine. Key findings: A number of risk factors for breast cancer have been identified. These include advancing age, hormonal factors (eg. early menarche, late menopause and late age at first full-term pregnancy), familial risk, BRCA-1 and BRCA-2 gene mutations, diet and postmenopausal obesity. Several interventions have been introduced to assist women at high risk for breast cancer, including genetic counseling and testing for women who have strong family histories of breast cancer; selective estrogen receptor modifiers, such as tamoxifen, that has been shown to reduce breast cancer rates; prophylactic mastectomy and screening. Data gaps and recommendations: Guidelines are unclear in several areas, particularly in screening. Where clinical guidelines are available, health services research or ongoing monitoring (by provincial/territorial cancer agencies) is needed to assess compliance with the guidelines and to ensure equity of access within the provinces/territories. Key components of organized screening programs need to be established, in part to ensure that screening is carried out in high-quality, co-ordinated programs. There is also a need to develop ways to involve women fully in informed decision-making and to address several policy issues to prevent disparities in access to high-quality services. Patenting issues associated with genetic tests also need to be clarified. © Bryant; licensee BioMed Central Ltd 2004. This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
引用
收藏
相关论文
共 50 条
  • [31] Tamoxifen and fenretinide in women with metastatic breast cancer
    Zujewski, J
    Pai, L
    Wakefield, L
    Giusti, R
    Dorr, FA
    Flanders, C
    Caruso, R
    Kaiser, M
    Goodman, L
    Merino, M
    Gossard, M
    Noone, MA
    Denicoff, A
    Venzon, D
    Cowan, KH
    O'Shaughnessy, JA
    BREAST CANCER RESEARCH AND TREATMENT, 1999, 57 (03) : 277 - 283
  • [32] Management of hot flashes in women with breast cancer
    Kligman, L.
    Younus, J.
    CURRENT ONCOLOGY, 2010, 17 (01) : 81 - 86
  • [33] The development of endocrine therapy for women with breast cancer
    Sainsbury, Richard
    CANCER TREATMENT REVIEWS, 2013, 39 (05) : 507 - 517
  • [34] Switching of Hormone Therapies in Breast Cancer Women
    de Medeiros, Luana Moreira
    Stahlschmidt, Rebeca
    Ferracini, Amanda Canato
    de Souza, Cinthia Madeira
    Teatin Juliato, Cassia Raquel
    Mazzola, Priscila Gava
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2021, 43 (03): : 185 - 189
  • [35] Tamoxifen and fenretinide in women with metastatic breast cancer
    J. Zujewski
    L. Pai
    L. Wakefield
    R. Giusti
    F.A. Dorr
    C. Flanders
    R. Caruso
    M. Kaiser
    L. Goodman
    M. Merino
    M. Gossard
    M.A. Noone
    A. Denicoff
    D. Venzon
    K.H. Cowan
    J.A. O'Shaughnessy
    Breast Cancer Research and Treatment, 1999, 57 : 277 - 283
  • [36] Management of women with a hereditary predisposition for breast cancer
    Jatoi, Ismail
    Benson, John R.
    FUTURE ONCOLOGY, 2016, 12 (19) : 2277 - 2288
  • [37] Tamoxifen and the Risk of Endometrial Cancer in Japanese Women with Breast Cancer
    Koji Yamazawa
    Yukimasa Miyazawa
    Masato Suzuki
    Maki Wakabayashi
    Hiroshi Kaku
    Hideo Matsui
    Souei Sekiya
    Surgery Today, 2006, 36 : 41 - 46
  • [38] Chemotherapy and cognitive complaints in women with breast cancer
    Pullens, Marleen J. J.
    De Vries, Jolanda
    Van Warmerdam, Laurence J. C.
    De Wal, Marieke A. Van
    Roukema, Jan A.
    PSYCHO-ONCOLOGY, 2013, 22 (08) : 1783 - 1789
  • [39] Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy
    Green L.E.
    Dinh T.A.
    Hinds D.A.
    Walser B.L.
    Allman R.
    Applied Health Economics and Health Policy, 2014, 12 (2) : 203 - 217
  • [40] Breast cancer prevention in older women: an algorithm to choose an optimal preventive agent
    Ozdemir, Burcu Z.
    Goodin, Joel B.
    Bodenner, Donald L.
    BREAST CANCER-TARGETS AND THERAPY, 2019, 11 : 81 - 86